Drugs / GAM501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00065663 | Aug 2002 → Dec 2004 | diabetes mellitus, ulcer of lower limbs | Tissue Repair Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00493051 Comparator | Nov 2007 → Dec 2009 | — | Tissue Repair Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GAM501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00493051 ↗ |
| Route | Topical | “topical applications of GAM501” NCT00065663 ↗ |
| Target | PDGFB | “GAM501, a gene for PDGF-B contained within an E1-deleted adenoviral vector” NCT00065663 ↗ |